BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

October 31, 2011 7:00 AM UTC

Affymax Inc. (NASDAQ:AFFY) was up $0.22 to $5.33 last week after saying that FDA's Oncologic Drugs Advisory Committee (ODAC) will meet on Dec. 7 to discuss an NDA for peginesatide to treat anemia in chronic kidney disease (CKD) patients on dialysis. The PDUFA date is March 27.

Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) gained $0.05 to $1.37 last week after FDA said the Psychopharmacologic Drugs Advisory Committee will meet on Dec. 12 to discuss the company's NDA for Adasuve loxapine to treat agitation in patients with schizophrenia or bipolar disorder. The PDUFA date is Feb. 4. Alexza also submitted an MAA to EMA for Adasuve in the same indication...